Why hospitals don’t sell linezolid

Linezolid (Linezolid), as a representative of oxazolidinone antibacterial drugs, is widely used to treat multiple drug-resistant bacterial infections. Due to its unique mechanism of action and high activity against Gram-positive bacteria, it occupies an important position in the global medical system. It exerts a bacteriostatic effect by blocking bacterial protein synthesis and is thus used clinically to treat conditions where other antibiotics are not effective enough. Especially in the context of the increase in complicated infections and pathogenic bacteria that are resistant to multiple conventional drugs, linezolid has become one of the drugs with clear value in international guidelines.

It can cover special drug-resistant bacteria including methicillin-resistant Staphylococcus aureus, making it an important choice in respiratory tract infections, skin and soft tissue infections, and other serious infections. With the emergence of more nosocomial drug-resistant strains in human society in recent years, linezolid's professionalism and clinical status have continued to improve, which has attracted increasing attention among various patient groups.

As for the question of "why hospitals don't sell linezolid" involves comprehensive considerations of national drug management, hospital drug catalog setting and use risks. First of all, linezolid is a strictly regulated antibacterial drug, and its clinical use must comply with the antibiotic hierarchical management system. Linezolid may be included as a "restricted grade" or "specialty use grade" antibacterial drug, meaning that not all hospitals can freely purchase and use it. Only hospitals with specific qualifications and relevant disciplinary capabilities are qualified to include it in the pharmacy directory and carry out standardized use.

Secondly, considering its potential adverse reactions, such as bone marrow suppression, neuropathy, lactic acidosis and other risks, it requires the clinical team to have continuous monitoring capabilities. Therefore, some primary hospitals may choose not to introduce this type of drug if they have insufficient technical reserves. Furthermore, the price of linezolid’s original drug is relatively high, and hospitals usually make dynamic adjustments based on local medical insurance policies and patient affordability when distributing drugs.

Reference materials:https://go.drugbank.com/drugs/DB00601